Neuromyelitis Optica

Advocacy intelligence hub — real-time data for patient organizations

View full disease page →Search clinical trials →
Download CSV

At a Glance

Live from database

Regulatory Watchboard

10 events
May 2026Rituximab Versus Ravulizumab, Inebilizumab, Satralizumab, and Eculizumab in NMOSD

Massachusetts General Hospital — PHASE4

TrialNOT YET RECRUITING
Apr 2026Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA® During Pregnancy

Amgen

TrialRECRUITING
Mar 2026A Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)

Hoffmann-La Roche — PHASE3

TrialRECRUITING
Jan 2026Autonomic Dysfunction in Neuromyelitis Optica Spectrum Disorder and Multiple Sclerosis : A Comparative Study

Mohamed Moshref abd alsattar

TrialNOT YET RECRUITING
Jan 2026Multiple Sclerosis Versus Neuromyelitis Optica Spectrum Disorder

Assiut University

TrialNOT YET RECRUITING
Jan 2026Modified Zipper Therapy for AQP4-IgG Positive Neuromyelitis Optica Spectrum Disorder

Tianjin Medical University General Hospital — PHASE4

TrialRECRUITING
Dec 2025Safety and Efficacy of BAFFR CART for Relapsed/ Refractory Neuromyelitis Optica Spectrum Disorder

Tianjin Medical University General Hospital — PHASE1, PHASE2

TrialNOT YET RECRUITING
Dec 2025Prospective Cohort Study of Neuromyelitis Optica Spectrum Disorders (NMOSD)

Xiamen Hospital of Traditional Chinese Medicine

TrialNOT YET RECRUITING
Oct 2025Efficacy and Safety of Monoclonal Antibody in Acute Phase of Neuromyelitis Optica Spectrum Disorder

First Affiliated Hospital of Chongqing Medical University

TrialNOT YET RECRUITING
Sep 2025Slow vs. Rapid Glucocorticoids Tapering With Inebilizumab in NMOSD

Tianjin Medical University General Hospital — PHASE3

TrialNOT YET RECRUITING

Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Financial Assistance

17 programs

FINANCIAL LANDSCAPE SUMMARY

17

Total programs

8

Open now

2

Copay cards

15

Travel grants

Copay Assistance2

UPLIZNA

Amgen

OpenContact for detailsApply ↗

Enspryng

Genentech

OpenContact for detailsApply ↗

Travel Grants15

AMGEN Assist

Amgen

Contact for detailsApply ↗

Amgen Assist 360

Amgen

OpenContact for detailsApply ↗

Amgen By Your Side Patient Assistance Program: Uplizna

Amgen

OpenContact for detailsApply ↗

Amgen Patient Assistance Program

Amgen

Contact for detailsApply ↗

Amgen Support Plus

Amgen

Contact for detailsApply ↗

Amgen SupportPlus Patient Support Program

Amgen

OpenContact for detailsApply ↗

Enspryng Co-Pay Program

The Assistance Fund

OpenContact for detailsApply ↗

Genentech Access to Care

Genentech

Contact for detailsApply ↗

Genentech Patient Assistance

Genentech

Contact for detailsApply ↗

Genentech Transplant Access Services (GTAS)

Genentech

Contact for detailsApply ↗

Neuromyelitis Optica Spectrum Disorder Financial Assistance Program

The Assistance Fund

OpenContact for detailsApply ↗

NORD RareCare Patient Assistance Program

National Organization for Rare Disorders, Inc. (NORD)

OpenContact for detailsApply ↗

PAN Foundation Neuromyelitis Optica Spectrum Disorder Fund

PAN Foundation

ClosedUp to $8K/yrApply ↗

PAN Foundation Neuromyelitis Optica Spectrum Disorder Patient Assistance Grant

PAN Foundation

ClosedUp to $8K/yrApply ↗

The Assistance Fund (TAF) Neuromyelitis Optica Spectrum Disorder Fund

The Assistance Fund

Contact for detailsApply ↗

View all support programs on disease page →

Clinical Trial Landscape

28 active trials
4Phase 3
2Phase 4
2Phase 2
1Phase 1
4N/A
9Unknown
3PHASE2, PHASE3
2PHASE1, PHASE2
1EARLY_PHASE1
28Total recruiting
Search clinical trials for Neuromyelitis Optica

Recent News & Research

No recent news articles indexed yet for Neuromyelitis Optica.
Search PubMed for Neuromyelitis Optica

Browse all Neuromyelitis Optica news →

Specialist Network

Top 6 by expertise

View all Neuromyelitis Optica specialists →

Quick Actions